MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.4869
-0.0290
-5.62%
After Hours: 0.4851 -0.0018 -0.37% 19:49 09/11 EDT
OPEN
0.5200
PREV CLOSE
0.5159
HIGH
0.5230
LOW
0.4769
VOLUME
562.95K
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.2300
MARKET CAP
9.47M
P/E (TTM)
-0.1769
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENSC last week (0831-0904)?
Weekly Report · 6d ago
Ensysce completes enrollment for final phase of PF614-MPAR-102 study
TipRanks · 08/31 12:40
Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study
Benzinga · 08/31 12:35
Weekly Report: what happened at ENSC last week (0824-0828)?
Weekly Report · 08/31 10:32
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
TipRanks · 08/25 22:01
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
TipRanks · 08/24 21:28
Weekly Report: what happened at ENSC last week (0817-0821)?
Weekly Report · 08/24 10:33
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
Barchart · 08/20 07:00
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.